A Novel FLCN Variant in a Suspected Birt-Hogg-Dubè Syndrome Patient.
Erika BandiniValentina ZampigaIlaria CanginiMila RavegnaniValentina ArcangeliTania RossiIsabella MammiFrancesca SchiaviStefania ZovatoFabio FalciniDaniele CalistriRita DanesiPublished in: International journal of molecular sciences (2023)
Subjects with pathogenic (PV) and likely pathogenic (LPV) FLCN variants have an increased risk of manifesting benign and malignant disorders that are related to Birt-Hogg-Dubé syndrome (BHDS): an autosomal dominantly inherited disorder whose severity can vary significantly. Renal cell carcinoma (RCC) development in BHD (Birt-Hogg-Dubé) patients has a very high incidence; thus, identifying this rare syndrome at early stages and preventing metastatic spread is crucial. Over the last decade, the advancement of Next Generation Sequencing (NGS) and the implementation of multigene panels for hereditary cancer syndromes (HCS) have led to a subsequent focus on additional genes and variants, including those of uncertain significance (VUS). Here, we describe a novel FLCN variant observed in a subject manifesting disorders that were suspected to be related to BHDS and with a family history of multiple cancers.
Keyphrases